The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.

中文翻译：

---

奥马珠单抗对慢性自发性荨麻疹患者血清P物质、降钙素基因相关肽、神经肽Y、白细胞介素31水平的影响

奥马珠单抗治疗荨麻疹的作用机制目前尚不清楚。本研究检查了使用奥马珠单抗的患者 P 物质 (SP)、降钙素基因相关肽 (CGRP)、神经肽 Y (NPY) 和白细胞介素 31 (IL-31) 的血清值。在这项研究中，30 名即将接受奥马珠单抗治疗的慢性自发性荨麻疹 (CSU) 患者和 20 名健康志愿者参与了这项研究。记录了人口统计数据、临床数据和疾病活动评分。血清SP、CGRP、NPY、IL-31值分别在治疗开始前、治疗后3个月、第6个月末以及健康志愿者中一次性抽取10 mL血液。通过弗里德曼检验分析基线、第 3 个月和第 6 个月测量值的变化。Mann-Whitney U检验用于比较从患者和对照组获得的参数。显着性水平设定为。与对照组相比，CSU 患者组的 SP、CGRP、NPY 和 IL-31 值均显着降低。治疗后血清SP、CGRP水平升高，血清IL-31水平下降。这些变化具有统计学意义。这项研究支持这样的观点，即奥马珠单抗不仅影响 IgE 受体，还通过其他机制影响肥大细胞。据我们所知，这是第一项表明奥马珠单抗治疗与血清 CGRP 水平相关的研究。